Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: Results of the managing anticoagulation services trial

American Journal of Medicine

Volumn 113, Issue 1, 2002, Pages 42-51

  Matchar, David B ^a,b,c   Samsa, Gregory P ^a,b   Cohen, Stuart J ^d   Oddone, Eugene Z ^a,b,c   Jurgelski, Annette E ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MANAGED CARE PROGRAMS; PROTHROMBIN TIME; QUALITY OF HEALTH CARE; RISK FACTORS; UNITED STATES; WARFARIN;

EID: 0036066718     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01131-2     Document Type: Article

References (39)

1. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study
2. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study
3. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
4. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
5. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators
6. Stroke prevention in atrial fibrillation study: Final results
7. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
8. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
9. Medical treatment for stroke prevention
10. Antithrombotic therapy in atrial fibrillation
11. Guidelines for the management of transient ischemic attacks
12. Warfarin use among patients with atrial fibrillation
13. National patterns of warfarin use in atrial fibrillation
14. Quality of anticoagulation management among patients with atrial fibrillation: Results from a review of medical records from two communities
15. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice?
16. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group
17. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation
18. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
19. Optimal oral anticoagulant therapy in patients with mechanical heart valves
20. Risk factors for intracranial hemorrhage in outpatients taking warfarin
21. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
22. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin
23. Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions
24. A seven-step model for practice improvement research: Description and application to the MAST
25. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management
26. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force
27. Managing oral anticoagulant therapy (Sixth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy)
28. Anticoagulation management as a risk factor for adverse events: Grounds for improvement
29. Should we just let the anticoag-ulation service do it? The conundrum of anticoagulation for atrial fibrillation
30. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
31. A method to determine the optimal intensity of oral anticoagulant therapy
32. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
33. Relationship between test frequency and outcomes of anticoagulation: A literature review and commentary with implications for the design of randomized trials of patient self-management
34. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
35. Comparison of an anticoagulation clinic with usual medical care
36. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: A randomized, controlled trial
37. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy
38. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized controlled trial